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Abstract: Background: Broadly cross-reactive, neutralizing human monoclonal antibodies, including 2F5, 2G12, 4E10 
and IgG1 b12, can inhibit HIV-1 infection in vitro at very low concentrations. We examined the ability of these antibodies 
to inhibit cell-cell fusion between Clone69TRevEnv cells induced to express the viral envelope proteins, gp120/gp41 
(Env), and highly CD4-positive SupT1 cells. The cells were loaded with green and red-orange cytoplasmic fluorophores, 
and fusion was monitored by fluorescence microscopy. 
Results: Cell-cell fusion was inhibited completely by the carbohydrate binding proteins (CBPs), Hippeastrum hybrid 
(Amaryllis) agglutinin (HHA), and Galanthus nivalis (Snowdrop) agglutinin (GNA), and by the peptide, T-20, at 
relatively low concentrations. Anti-gp120 and anti-gp41 antibodies, at concentrations much higher than those required for 
neutralization, were not particularly effective in inhibiting fusion. Monoclonal antibodies b12, m14 IgG and 2G12 had 
moderate inhibitory activity; the IC50 of 2G12 was about 80 g/ml. Antibodies 4E10 and 2F5 had no inhibitory activity at 
the concentrations tested. 
Conclusions: These observations raise concerns about the ability of neutralizing antibodies to inhibit the spread of viral 
genetic material from infected cells to uninfected cells via cell-cell fusion. The interaction of gp120/gp41 with cell 
membrane CD4 may be different in cell-cell and virus-cell membrane fusion reactions, and may explain the differential 
effects of antibodies in these two systems. The fluorescence assay described here may be useful in high throughput 
screening of potential HIV fusion inhibitors. 
Keywords: Fluorescence microscopy, HIV infection, membrane fusion, fusion inhibitor, HIV vaccine, carbohydrate binding protein. 
INTRODUCTION 
  Human immunodeficiency virus type 1 (HIV-1) infects 
its host cells by the initial specific interaction of the HIV-1 
envelope glycoprotein Env (gp120/gp41) with the CD4 
molecule found primarily on T helper lymphocytes and 
macrophages [1,2]. Entry of HIV-1 into target cells requires 
formation of a complex between the Env glycoprotein 
gp120, the primary receptor CD4, and a co-receptor. The 
chemokine receptors CXCR4 (X4) and CCR5 (R5) have 
been identified as the principal co-receptors for X4 (T cell 
tropic) and R5 (macrophage tropic) viruses, respectively. 
Binding of gp120 to the N-terminal domain of CD4 induces 
a pH-independent conformational change in both molecules, 
resulting in the interaction of the fusion domain at the N 
terminus of the transmembrane gp41 with the target cell 
membrane. gp41 then folds back on itself and forms a six-
helix bundle, bringing the viral and cellular membranes into 
close proximity, and also forcing the fusion of the two 
membranes [3]. 
  Broadly cross-reactive, neutralizing human monoclonal 
antibodies can inhibit HIV-1 infection in vitro; however   
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administration of these antibodies to HIV-1-infected patients 
has resulted in only modest antiviral activity [4]. There may 
be a number of reasons for this observation, including access 
of the antibodies to sites of active virus infection. It is also 
possible that, while these antibodies inhibit virus-cell fusion, 
they do not inhibit cell-cell fusion, and hence enable the 
spread of the virus via syncytium formation. 
  The human monoclonal antibody 2F5 neutralizes a 
variety of HIV-1 laboratory strains and clinical isolates, and 
interacts with the gp41 ectodomain, close to the 
transmembrane region [5] (Table 1). The inhibitory activity 
of the antibody was evaluated by pre-incubating it with the 
virus, adding the mixture to AA-2 cells, and measuring 
syncytium formation 5 days later. The IC50 values were 3.7, 
0.7 and 0.8 g/ml for the IIIB, MN and SF2 isolates, 
respectively [6]. By contrast, the 50%-effective 
concentration of 2F5 for inhibiting the fusion of chronically 
infected H9 cells with AA-2 cells was 21.0, 19.3 and 17.7 
g/ml, respectively, indicating that much higher 
concentrations of antibody were necessary to inhibit cell-cell 
fusion in this system. The 4E10 antibody inhibited the 
infection of AA-2 cells by IIIB, MN and RF isolates, 
measured by the presence or absence of syncytium formation 
5 days after inoculation, at IC50s of 1.0, 0.3 and 12.5 g/ml, 
respectively [7]. 
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  The recombinant monoclonal antibody, IgG1 b12, is 
directed to the CD4-binding site of gp120 from the IIIB 
strain of HIV-1 [8]. It had 50% neutralization titers of 3 
ng/ml against the MN strain, and 7 ng/ml against IIIB, as 
determined by the inhibition of plaque formation. The 
monoclonal antibody, 2G12, binds to a conformational 
carbohydrate-based epitope on gp120 [9], and neutralizes 
HIV-1 strains IIIB, RF, and MN at ID50s of 0.02, 0.13 and 
1.56  g/ml, respectively [10]. It also neutralizes a broad 
range of primary isolates in a PBMC-based assay at ID50 
concentrations in the range of <0.01–0.15 g/ml, but it is 
ineffective against other isolates. In a syncytium inhibition 
assay involving AA-2 cells, 2G12 antibody had EC50s of 4.6 
and 0.5 g/ml for IIIB and RF, respectively, but it did not 
inhibit syncytium formation directed by the MN isolate (> 60 
g/ml), consistent with its inability to achieve 90% 
neutralization with this virus with respect to inhibition of 
virus production in AA-2 cells. The antibody IgG1 m14 
originated from a human Fab phage display library based on 
inhibition of gp120 binding to soluble CD4 [11]. Fab m14 
neutralized the HxB2 isolate with an IC50 of 1 g/ml. 
  The fusion activity of Env can be studied conveniently by 
the fusion of HIV-1-infected cells with uninfected CD4+ 
cells [12]. Alternatively, cells expressing the Env protein in 
the absence of infection can be utilized for this purpose. We 
developed a new HIV fusion assay, using Clone69TRevEnv 
cells that express Env cloned from the IIIB (HXB) strain 
when tetracycline is removed from the medium [13]. SupT1 
cells that express CD4 at high levels [14,15] were used as 
target cells. The use of Clone69TRevEnv cells cultured in 
tetracycline also provides a convenient control in which Env 
is not expressed. For the fluorescence assay, 
Clone69TRevEnv cells were labeled with a green fluorescent 
dye that is trapped in the cytoplasm following permeation 
through the plasma membrane. SupT1 cells were labeled 
with a red fluorescent dye that is trapped in the same 
manner. Env-mediated fusion between these fluorescently 
labeled cells is observed by the formation of orange syncytia. 
MATERIALS AND METHODOLOGY 
Cells 
  Clone69TRevEnv cells from Dr. Joseph Dougherty were 
obtained through the AIDS Research and Reference Reagent 
Program, Division of AIDS, NIAID, NIH (ARRRP; 
Germantown, MD). They were maintained at 37°C, under 
5% CO2 in Dulbecco’s modified Eagle’s MEM 
supplemented with 10% (v/v) heat-inactivated fetal bovine 
serum (FBS), L-glutamine (4 mM) (all from the UCSF Cell 
Culture Facility, San Francisco, CA), geneticin (200 g/ml), 
hygromycin B (100 g/ml; GIBCO, Grand Island, NY) and 
tetracycline (2.0 g/ml; Sigma, St. Louis, MO) 
(“DME/10*+tet”). To enable Env expression, the “Env
–
“cells were transferred to medium without tetracycline 
(“DME/10*–tet”) 7 days before the experiment [13]. The 
cells were plated at 2.0 x 10
5 cells/ml in 48-well plates for 24 
h. Tetracycline causes tTa, a fusion protein consisting of the 
tetracycline repressor and activation domain of the herpes 
simplex virus VP16 protein, to undergo a conformational 
change that prevents the binding of tTa to the inducible 
promoter. This prevents Rev expression, inhibiting the 
expression of Env. The absence of tetracycline leads to Rev 
expression and transfer of late protein transcripts to the 
cytoplasm, allowing for the expression of Env and producing 
the “Env
+” cells [13]. Env was shown to mediate fusion with 
HeLaT4 cells, and is thus T-tropic. In our experiments, 
highly CXCR4-positive SupT1 cells were used as the target 
cells, further indicating that Env expressed by 
Clone69TRevEnv cells is T-tropic. 
  SupT1 cells [14] were obtained from Dr. James Hoxie 
through the ARRRP. They were maintained at 37°C, under 
5% CO2 in RPMI 1640 medium supplemented with 10% 
FBS, penicillin (100 units/ml), streptomycin (100 g/ml) and 
L-glutamine (2 mM) (RPMI/10) (all from the UCSF Cell 
Culture Facility). SupT1 cells (2.0 x 10
5) were added to 
wells containing adherent HIV-Env cells incubated 
previously with or without tetracycline. 
Lectins 
 Hippeastrum hybrid (Amaryllis) agglutinin (HHA) and 
Galanthus nivalis agglutinin (GNA) were prepared as 
described by Van Damme et al. [16]. They were dissolved in 
phosphate buffered saline (PBS), and were added at varying 
concentrations to plated Env
+ cells. 
Fusion Inhibitor 
  The N-acetylated derivative of the Trimeris/Roche T-20 
fusion inhibitor [17,18] was obtained through the ARRRP, 
dissolved in PBS, and added to plated Env
+ cells expressing 
the envelope protein at varying concentrations. 
Table 1.  The Molecular Targets and IC50 Values of the Antibodies Evaluated in this Study, and the HIV-1 Strains they Inhibit 
 
Antibody  Molecular Target  HIV Isolates Inhibited  Target Cells Used for IC50  
Determination for IIIB 
IC50 for HIV-1IIIB  
(g/ml)
‡ 
References 
IgG1 b12   gp120  IIIB, MN and some primary isolates   H9†  0.007   [8] 
2G12   gp120  IIIB, RF, MN (weakly), SF2 (weakly)   AA-2  0.02   [9] [10] 
IgG1 m14    gp120  IIIB (HxB2), JRCSF, 89.6, Yu2  U87.CD4.CCR5.CXCR4  1.0   [11] 
4E10   gp41  IIIB, MN, RF (weakly) & broad range of isolates  AA-2
§ 1.0
§   [7] 
2F5   gp41  IIIB, MN, SF2 & broad range of isolates  
H9 
U937 
PBMC 
0.3 
0.13 
0.8 
[6] 
‡IC50 values were derived from infectivity measurements utilizing free virus, and subsequent p24 production, unless indicated otherwise. 
§Cells were infected with cell-free virus and syncytium formation after 5 days was used as the readout. 
†IC50 values were derived from a plaque assay. 46    The Open Virology Journal, 2011, Volume 5  Yee et al. 
Antibodies 
  The following monoclonal antibodies to HIV-1 gp120 
were used (Table 1): IgG1B12 (“B12”) [8] was obtained 
from Dr. Dennis Burton and Carlos Barbas (through the 
ARRRP). hmAb 2G12 was purchased from Polymun 
Scientific (Vienna, Austria), m14 IgG was a gift of Dr. D. 
Dimitrov (NIH), and F105 [19,20] was provided by Dr. Dr. 
Marshall Posner and Dr. Lisa Cavacini through the ARRRP. 
The anti-HIV-1 gp41 monoclonal antibodies 2F5 [6] and 
4E10 [7] were obtained from Dr. Hermann Katinger through 
the ARRRP. The antibodies were diluted in PBS and added 
to the Clone69TRevEnv cells before the addition of SupT1 
cells, at varying concentrations. 
Fluorescence Labelling 
 Env
– and Env
+ Clone69TRevEnv cells were labeled with 
Calcein AM Green (Invitrogen, Carlsbad, CA) at 
concentrations of 1 or 2 M for 30 min at 37°C. Excess dye 
was removed by washing the cells twice with PBS. SupT1 
cells were labeled with CellTrace™ Calcein red-orange 
(Invitrogen) at concentrations of 2 or 4 M for 30 min at 
37°C. Excess dye was removed by washing the cells twice 
with PBS. 
The Fusion Assay 
  Fluorescently labeled Clone69TRevEnv cells (2 x 10
5 
cells/well in a 48-well plate) were incubated for 30 min in 
PBS, with or without antibodies, lectins, or fusion inhibitor. 
An equivalent number of labeled SupT1 cells in PBS were 
added to the Env
+  or Env
– cells, and incubated for 3 h at 
37°C, under 5% CO2. The cells were then washed twice with 
PBS, and observed with a 20x objective in a Nikon Diaphot 
inverted fluorescence microscope equipped with a dual 
fluorescence filter cube (Chroma, Bellows Falls, VT). 
Micrographs were obtained either with a QImaging camera 
using the Qcapture program on an Apple Power Macintosh 
G3 computer, or a Jenoptik ProgRes digital camera system 
using ProgRes MAC CapturePro software and an Apple 
iMac computer. The dose-response curves were generated 
from duplicate wells. Other experiments were performed 
with triplicate wells for each condition, and the results 
presented are representative of at least two independent 
experiments. 
RESULTS 
Cell-Cell Fusion 
  Clone69TRevEnv cells maintained in tetracycline-
containing medium (Env
– cells) do not express the envelope 
protein gp120/gp41. These cells (green) did not fuse with the 
SupT1 cells (red-orange) (Fig. 1A). Clone69TRevEnv cells 
grown without tetracycline (Env
+ cells) express gp120/gp41. 
When these cells were incubated in the presence of SupT1 
cells they produced orange syncytia, primarily in the shape 
of the adherent cells (Fig. 1B). In some experiments, 
syncytium formation was more extensive (Fig. 1C). 
Effect of Lectins 
  A number of carbohydrate-binding proteins (CBP) that 
specifically recognize mannose (Man) and N-
acetylglucosamine (GlcNAc) have a remarkable anti-HIV 
activity in cell culture [21,22]. They not only inhibit 
infection by cell-free virus, but they can also prevent 
efficiently virus transmission from virus-infected cells to 
uninfected T-lymphocytes. In our experiments, Hippeastrum 
hybrid (Amaryllis) agglutinin (HHA) inhibited completely 
the fusion between the Env
+ cells and SupT1 cells (Fig. 2A, 
B). Similar results were obtained with Galanthus nivalis 
(Snowdrop) agglutinin (GNA) (data not shown). These 
lectins also inhibited the binding of the red SupT1 cells to 
the adherent Env
+ cells (Fig. 2A), in contrast to the 
observations with T-20, which did not inhibit binding (Fig. 
2C), as expected, since the peptide interacts with gp41. 
Effect of the Fusion Inhibitor, T-20 
  The peptide DP-178 corresponds to a region predictive of 
an alpha-helical secondary structure, namely residues 643-
678 of the gp160 of the HIV-1LAI isolate [20]. It has shown 
significant anti-HIV activity, and has been developed as the 
first HIV entry inhibitor, T-20 [18]. This peptide consistently 
blocked 100% of virus-mediated cell-cell fusion at < 5 ng/ml 
[17]. In our experiments, T-20 was also highly inhibitory to 
fusion between Env
+ cells and SupT1 cells, with an 
approximate IC50 of 0.05 g/ml (Fig. 2C, D). 
Effect of Antibodies 
  We examined whether antibodies reported to inhibit HIV 
infection by a wide range of HIV-1 isolates, including IIIB, 
also inhibit Env-mediated membrane fusion in our novel 
 
Fig. (1). Syncytium formation between Clone69TRevEnv and SupT1 cells. (A) Env
– cells that do not express gp120/gp41 did not form 
syncytia with SupT1 cells. (B). Env
+ cells expressing gp120/gp41 formed syncytia with SupT1 cells in PBS. (C) Cells as in B, but observed 
in a different experiment. The cells were incubated with each other for 3 h at 37˚C, washed twice with PBS, and then observed by 
fluorescence microscopy using a dual filter. 
 
–
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assay. Monoclonal anti HIV-1 gp120 antibodies, b12, m14 
IgG, F105 and 2G12, and anti-gp41 antibodies, 2F5 and 
4E10, in the range of 1–10 g/ml, were not very effective in 
inhibiting syncytium formation (Figs. 3,  4). The IC50 for 
2G12 antibody was approximately 80 g/ml (Fig. 3B). The 
percentage of fused cells in the controls varied from 
experiment to experiment. In the experiment shown in Fig. 
(4), the percentages of fused cells were 23% with both 4E10 
(Fig. 4A) and 2F5 (Fig. 4B), 14% with both b12 (Fig. 4C) 
and m14 IgG (Fig. 4D), and 11% with 2G12 (Fig. 4E), 
whereas the percentage of fused cells in the untreated 
controls for this experiment was 20% (Fig. 4F). Thus, b12 
and m14 IgG inhibited cell-cell fusion by about 30%, 
whereas 2G12 (at 10 g/ml) inhibited fusion by about 45%. 
Even at 50 g/ml, 2G12 antibody had a similar inhibitory 
activity (12% fused cells). In the case of the anti-gp41 
antibodies, 4E10 and 2F5, there were numerous red SupT1 
cells attached to the Env
+ cells, since these antibodies are not 
expected to inhibit the interaction of gp120 with CD4, and 
hence the binding of the CD4+ cells to Env-expressing cells. 
Nevertheless, these antibodies did not inhibit Env-mediated 
cell-cell fusion. 
DISCUSSION 
  Several fluorescence methods to study HIV-induced cell-
cell fusion have been described previously. These include 
the transfer of the membrane probe DiI or the cytoplasmic 
probe (BCECF) from labeled cells to unlabeled cells [23,24]. 
Frey et al. [25] described a method where a fluorescent fatty 
acid probe was incorporated metabolically into SupT1 cells, 
and the dilution of the probe into unlabeled cells was 
monitored. The principle of the assay used in this study is 
similar to that described by Muñoz-Barroso et al. [26], who 
used B cell-derived TF228.1.6 cells that express 
 
Fig. (2). The effect of HHA and T-20 on syncytium formation between Env
+ and SupT1 cells. Env+ cells were incubated with the reagents 
for 30 min before the addition of the SupT1 cells. The cells were then incubated for 3 h at 37˚C, washed twice with PBS, and then observed 
by fluorescence microscopy. (A) Fluorescence micrograph of cells incubated with HHA at 1 g/ml. HHA inhibited both the attachment of 
SupT1 cells to the Env
+ cells and their fusion. (B) Inhibition of cell-cell fusion by HHA at varying concentrations. (C) Fluorescence 
micrograph of cells incubated with T-20 at 1 g/ml. T-20 inhibited cell-cell fusion, but not the attachment of the red-orange SupT1 cells to 
the Env
+ cells. (D) Inhibition of cell-cell fusion by T-20 at varying concentrations. The vertical bars indicate the spread of duplicate 
determinations. 
B C 
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constitutively Env, and SupT1 cells. They labeled the former 
cells with the blue dye, CMAC, which interacts with free 
sulfhydryl groups inside cells, and the latter cells with both 
calcein and the membrane probe DiI. We used Calcein AM 
to label the cytoplasm of adherent Clone69TRevEnv cells, 
and the dye CellTrace™ Calcein red-orange to label the 
suspension SupT1 cells. An advantage of the 
Clone69TRevEnv cells is that they can be induced to express 
Env (Env
+), enabling us to use identical cells that do not 
express Env (Env
–) as controls. The use of an adherent-
suspension cell pair to monitor fusion is also advantageous, 
because the shape of the fusion product resembles that of 
adherent cells, in that it is spread out. This may be 
advantageous in a cell imaging-based screening system. 
Although there are many drugs that inhibit the HIV enzymes, 
reverse transcriptase and protease, there are only two 
approved drugs that inhibit virus entry into cells, Enfuvirtide 
and Maraviroc. The fluorescence assay described here may 
be useful in screening potential inhibitors of HIV-induced 
membrane fusion in high-throughput cell imaging assays. 
  The plant-derived, carbohydrate-binding proteins, HHA 
and GNA, and the peptide, T-20 (Enfuvirtide), markedly 
inhibited fusion in this assay system. CBP are thought to act 
by binding to the glycans on the HIV-1 gp120 envelope, and 
by cross-linking several glycans during virus-cell interaction 
[21]. They may freeze the conformation of gp120, 
consequently preventing further interaction with the HIV-1 
co-receptor(s) on the cell surface. Viruses resistant to 
inhibition by 2G12 antibody maintain their full sensitivity to 
various mannose-specific lectins [27]. Moreover, a 2G12-
resistant NL4.3 strain generated in vitro by antibody pressure 
was even more sensitive to mannose-specific lectins. Since 
T-20 inhibits the formation of the six-helix bundle of gp41 
[28], our results indicate that cell-cell fusion in our assay 
system is mediated by the gp41 protein component of Env. 
  Surprisingly, monoclonal antibodies that bind either of 
the two components of Env, gp120 and gp41, and that   
 
reportedly inhibit infection by a large number of HIV-1 
isolates, had little or no inhibitory effect on cell-cell fusion. 
We showed previously that a monoclonal antibody to the 
gp120-CD4 complex (Mab F-91-55) that bound the D1/D2 
domains of CD4 inhibited syncytium formation between 
chronically HIV-1-infected H9 cells and either A3.01 or 
Sup-T1 cells, even at a concentration of 0.1 g/ml [29]. 
However, the antibody had a very limited effect on HIV-1 
infection of A3.01 or Sup-T1 cells. This observation is in 
contrast to our current observations with the anti-gp120 and 
anti-gp41 antibodies that inhibit HIV-1 infection, but are not 
very effective in inhibiting syncytium formation. 
Nevertheless, Mab F-91-55 inhibited both the infectivity of 
HIV-1 in H9 cells, and syncytium formation between these 
cells and chronically infected H9 cells. We proposed earlier 
that cellular systems used for syncytium assays differ in their 
susceptibility to antibodies, and that the interaction of 
gp120/gp41 with cell membrane CD4 may be different in 
cell-cell and virus-cell membrane fusion [29]. This 
difference may also explain our current results. The 
molecular organization and surface density of gp120/gp41 
may be different in Env-expressing cells and HIV-1 virions. 
Purtscher  et al. [6] have explained their observations that 
significantly higher concentrations of antibody are necessary 
to inhibit fusion between infected cells and target cells by 
suggesting that higher levels of gp120/gp41 are expressed on 
the surface of infected cells. Choudhoury et al. [30] have 
found that the IC50 of 2F5 and 4E10 antibodies decreases by 
up to two orders of magnitude in cell lines with low cell 
surface expression of CCR5. Thus, the relatively high level 
of CXCR4 in the SupT1 cells used in our assay [15] may 
have also contributed to the limited ability of the tested 
antibodies to inhibit cell-cell fusion. 
  CBPs are smaller in size and bind in a much less specific 
manner to HIV gp120/gp41 than the mAbs. Thus, a higher 
number of CBPs can bind simultaneously to cell-surface 
Env. If the conformation of viral Env is different from that of  
 
 
Fig. (3). The effect of 2G12 antibody on syncytium formation between Env
+ cells and SupT1 cells. The Env+ cells were incubated with the 
antibodies for 30 min before the addition of the SupT1 cells. The cells were then incubated for 3 h at 37˚C, washed twice with PBS, and then 
observed by fluorescence microscopy. (A) Fluorescence micrograph of cells incubated with 10 g/ml 2G12 antibody. (B) Inhibition of cell-
cell fusion by 2G12 antibody at varying concentrations. The vertical bars indicate the spread of duplicate determinations. 
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Fig. (4). The effect of anti-Env antibodies on syncytium formation between Env
+ cells and SupT1 cells. The Env+ cells were incubated with 
the antibodies for 30 min before the addition of the SupT1 cells. The cells were then incubated for 3 h at 37˚C, washed twice with PBS, and 
then observed by fluorescence microscopy. (A) 4 g/ml 4E10 antibody; (B) 4 g/ml 2F5 antibody; (C) 4 g/ml IgG1 b12 antibody; (D) 4 
g/ml IgG1 m14 antibody. (E) 10 g/ml 2G12 antibody; (F) Untreated control cells. IgG1 b12 and IgG1 m14 had some fusion-inhibitory 
activity, whereas 4E10 and 2F5 antibodies were ineffective. The anti-gp41 4E10 and 2F5 antibodies did not inhibit the binding of the red-
orange SupT1 cells to the green Env
+ cells. 
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cell membrane Env, the efficiency of mAb binding to the 
latter may be compromised, whereas the affinity of the CBP 
binding to the gp120 glycans would be expected to be much 
less affected by conformational differences at the protein 
level. Therefore, the CBPs used in our study are very 
effective in blocking the fusion capacity even in the presence 
of a high density of Env, whereas the anti-gp120 and anti-
gp41 mAbs are rather poor inhibitors. 
  The limited inhibitory effect of the antibodies used in our 
experiments against Env-induced cell-cell fusion raises the 
possibility that such antibodies may not be able to inhibit 
efficiently the spread of viral genetic material from infected 
cells to uninfected cells via  cell-cell fusion. Two broadly 
neutralizing antibodies (PG9 and PG16) that recognize an 
epitope expressed on trimeric Env, and comprising 
conserved variable loops of gp120, have been identified 
recently [31]. Antibodies (VRC01 and VRC02) to the CD4 
receptor-binding site that neutralize over 90% of circulating 
HIV-1 strains have also been identified [32]. It has been 
suggested that vaccine-induced antibodies of similar 
specificity may provide protection against many HIV-1 
strains currently circulating. It will be of interest to examine 
the potential inhibitory effects of PG9, PG16, VRC01 and 
VRC02 antibodies on syncytium formation in our 
experimental system. 
CONCLUSION 
  The fluorescence assay described here may be useful in 
high throughput screening of potential HIV fusion inhibitors. 
The inability of HIV neutralizing antibodies to inhibit 
effectively HIV-Env-mediated syncytium formation fusion 
raises concerns about the ability of such neutralizing 
antibodies to inhibit the spread of viral genetic material from 
infected cells to uninfected cells via cell-cell fusion. CBPs 
appear to interact more efficiently with cell membrane Env 
than antibodies against gp120 and gp41, and are highly 
inhibitory to cell-cell fusion. 
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